Clinical Trial Update: Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating nivolumab in combination with dabrafenib and/or trametinib for metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Tafinlar) (dabrafenib)
• Trametinib (Mekinist) (trametinib)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: University of Pittsburgh | Conditions: Metastatic Melanoma | Phase 1 | Status: WITHDRAWN